[Mitoxantrone-cytarabine-etoposide induction therapy in children with acute myeloid leukemia: a single-center study of complications and clinical outcomes]

Zhongguo Dang Dai Er Ke Za Zhi. 2019 Jan;21(1):24-28. doi: 10.7499/j.issn.1008-8830.2019.01.005.
[Article in Chinese]

Abstract

Objective: To investigate the complications and clinical outcome of children with acute myeloid leukemia (AML) undergoing mitoxantrone-cytarabine-etoposide (MAE) induction therapy.

Methods: A total of 170 children with AML were given MAE induction therapy, and the complications and remission rate were analyzed after treatment.

Results: The male/female ratio was 1.33:1 and the mean age was 7.4 years (range 1-15 years). Leukocyte count at diagnosis was 29.52×109/L [range (0.77-351)×109/L]. Of all children, 2 had M0-AML, 24 had M2-AML, 2 had M4-AML, 48 had M5-AML, 3 had M6-AML, 7 had M7-AML, 69 had AML with t(8;21)(q22;q22), and 15 had AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22). The most common complication was infection (158/170, 92.9%). Among these 158 patients, 22 (13.9%) had agranulocytosis with pyrexia (with no definite focus of infection), and 136 (86.1%) had definite focus of infection (including bloodstream infection). Other complications included non-infectious diarrhea, bleeding, and drug-induced hepatitis. Treatment-related mortality was observed in 10 children, among whom 8 had severe infection, 1 had multiple organ failure, and 1 had respiratory failure. Remission rate was evaluated for 156 children and the results showed a complete remission rate of 85.3%, a partial remission rate of 4.5%, and a non-remission rate of 10.3%.

Conclusions: Induction therapy with the MAE regimen helps to achieve a good remission rate in children with AML after one course of treatment. Infection is the main complication and a major cause of treatment-related mortality.

目的: 回顾性分析米托蒽醌、阿糖胞苷联合依托泊苷(MAE)方案诱导治疗初诊儿童急性髓系白血病(AML)的合并症发生情况及疗效。

方法: 170例AML患儿采用MAE方案诱导治疗,分析诱导治疗后的合并症及缓解率。

结果: 170例中男女比例为1.33:1,年龄7.4(1~15)岁,诊断时WBC 29.52(0.77~351)×109/L,其中M0 2例、M2 24例、M4 2例、M5 48例、M6 3例、M7 7例,AML伴有t(8;21)(q22;q22)69例,AML伴有inv(16)(p13.1q22)或t(16;16)(p13.1;q22)15例。最常见的合并症为感染,占92.9%,其中无明确感染灶的粒缺伴发热占13.9%(22/158),有明确感染病灶(包括血流感染)的占86.1%(136/158);其他合并症包括非感染性腹泻、出血、药物性肝炎等。治疗相关死亡10例,其中严重感染8例、多脏器功能衰竭1例、呼吸衰竭1例。156例进行了缓解率评估,完全缓解率85.3%、部分缓解率4.5%、未缓解率10.3%。

结论: MAE方案治疗儿童AML的1疗程诱导缓解率较好,合并症及治疗相关死亡原因以感染为主。

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Child
  • Child, Preschool
  • Cytarabine
  • Drug Administration Schedule
  • Etoposide
  • Female
  • Humans
  • Infant
  • Leukemia, Myeloid, Acute* / drug therapy
  • Male
  • Mitoxantrone
  • Remission Induction

Substances

  • Cytarabine
  • Etoposide
  • Mitoxantrone